Last reviewed · How we verify
Renibus Therapeutics, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| RBT-1 | RBT-1 | phase 3 | ACE inhibitor | ACE | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
- Bioprojet · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Children's Hospital of Fudan University · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Renibus Therapeutics, Inc.:
- Renibus Therapeutics, Inc. pipeline updates — RSS
- Renibus Therapeutics, Inc. pipeline updates — Atom
- Renibus Therapeutics, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Renibus Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/renibus-therapeutics-inc. Accessed 2026-05-16.